Outcomes After Planned Discontinuation of AntiSeizure Medication
Public ClinicalTrials.gov record NCT07750496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to understand the effects of continuing versus discontinuing antiseizure medications after a period of seizure-freedom. Physician guidelines endorse that after a period of seizure-freedom, the risk of another seizure may be low enough to allow patients to consider coming off antiseizure medication to see if they still need it. However, evidence is limited regarding how much continuing antiseizure medication still reduces seizures versus increases side effects after a patient has been treated for a while. This study will determine whether discontinuing antiseizure medications benefits patients.
Study identification
- NCT ID
- NCT07750496
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 40 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2026
- Primary completion
- Jul 31, 2029
- Completion
- Jul 31, 2029
- Last update posted
- Aug 5, 2026
2026 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Epilepsy trials
Other public records listing Epilepsy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07768618: Electrophysiologic Mechanisms of Ketamine Antidepressant Response Not yet recruiting
- NCT07735715: HOBSCOTCH-YOUTH and Young Adults Not yet recruiting
- NCT06135285: A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position Not yet recruiting
- NCT05954182: Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) Active, not recruiting
- NCT04715646: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Recruiting
- NCT07721272: Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07750496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2026 · Synced Aug 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07750496 live on ClinicalTrials.gov.